doi: 10.1007/s10198-021-01285-1.
- PMID: 33880663
- DOI: 10.1007/s10198-021-01285-1
Abstract
Background: Uncertainty in model-based cost-utility analyses is commonly assessed in a probabilistic sensitivity analysis. Model parameters are implemented as distributions and values are sampled from these distributions in a Monte Carlo simulation. Bootstrapping is an alternative method that requires fewer assumptions and incorporates correlations between model parameters.
Methods: A Markov model-based cost-utility analysis comparing oromucosal spray containing delta-9-tetrahidrocannabinol + cannabidiol (Sativex®, nabiximols) plus standard care versus standard spasticity care alone in the management of multiple sclerosis spasticity was performed over a 5-year time horizon from the Belgian healthcare payer perspective. The probabilistic sensitivity analysis was implemented using a bootstrap approach to ensure that the correlations present in the source clinical trial data were incorporated in the uncertainty estimates.
Results: Adding Sativex® spray to standard care was found to dominate standard spasticity care alone, with cost savings of €6,068 and a quality-adjusted life year gain of 0.145 per patient over the 5-year analysis. The probability of dominance increased from 29% in the first year to 94% in the fifth year, with the probability of QALY gains in excess of 99% for all years considered.
Conclusions: Adding Sativex® spray to spasticity care was found to dominate standard spasticity care alone in the Belgian healthcare setting. This study showed the use of bootstrapping techniques in a Markov model probabilistic sensitivity analysis instead of Monte Carlo simulations. Bootstrapping avoided the need to make distributional assumptions and allowed the incorporation of correlating structures present in the original clinical trial data in the uncertainty assessment.
Keywords: Bootstrapping, Cannabinoids, Cost–utility analysis, Multiple sclerosis, Probabilistic sensitivity analysis
References
-
- Bodrogi, J., Kaló, Z.: Principles of pharmacoeconomics and their impact on strategic imperatives of pharmaceutical research and development. Br. J. Pharmacol. 159, 1367–1373 (2010). https://doi.org/10.1111/j.1476-5381.2009.00550.x – DOI – PubMed – PMC
- Olsen, J.A.: Principles in Health Economics and Policy. Oxford University Press, Oxford (2009) – DOI
- Szende, A., Oppe, M., Devlin, N.: EQ-5D Value Sets: Inventory, Comparative Review and User Guide. EuroQol Group Monographs. Springer, Dordrecht (2007) – DOI
- Gray, A.M., Clarke, P.M., Wolstenholme, J.L., Wordsworth, S.: Applied Methods of Cost-Effectiveness Analysis in Health Care. Oxford University Press, Oxford (2011)
- Drummond, M.F., Sculpher, M.J., Torrance, G.W., O’Brien, B.J., Stoddart, B.J.: Methods for the Economic Evaluation of Health Care Programmes, 3rd edn. Oxford University Press, Oxford (2005)
